Table 2 Gender‐specific variations among SSc subsets.
| dcSSc | p (♂ vs ♀) | lcSSc | p (♂ vs ♀) | |||
|---|---|---|---|---|---|---|
| Men | Women | Men | Women | |||
| Number of patients | 254 | 1094 | NA | 180 | 1910 | NA |
| Age (years), mean (SD) | 52.7 (12.6) | 52.3 (14.0) | 0.66 | 56.2 (13.2) | 57.5 (13.0) | 0.21 |
| Age at RO (years), mean (SD) | 46.4 (13.4) | 42.1 (14.9) | <0.001 | 47.1 (14.9) | 42.5 (14.4) | <0.001 |
| Age at first non‐RO (years), mean (SD) | 47.6 (13.1) | 44.1 (14.3) | 0.001 | 49.0 (14.1) | 47.8 (13.3) | 0.26 |
| Disease duration, years mean (SD) | 5.1 (5.0) | 7.9 (7.2) | <0.001 | 6.7 (5.7) | 9.8 (8.2) | <0.001 |
| Time between RO and first non‐RO (years), mean (SD) | 1.4 (4.7) | 2.0 (5.6) | 0.10 | 2.0 (5.2) | 5.1 (8.7) | <0.001 |
| ANA positive | 93.7% | 93.0% | 0.71 | 92.7% | 91.8% | 0.67 |
| Scl‐70 positive | 62.7% | 60.4% | 0.51 | 31.3% | 22.8% | 0.02 |
| ACA positive | 4.3% | 7.0% | 0.08 | 26.3% | 50.3% | <0.001 |
ACA, anticentromere autoantibody; ANA, antinuclear antibodies; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cutaneous systemic scerosis; SSC, Systemic sclerosis; RO, onset of Raynaud's phenomenon; ♂, male; ♀, female.